SGLT2i Treatment Reduces Cardiorenal Disease Risk in T2D Patients Without Established Cardiovascular and Renal Diseases: A Large Observational Study

被引：0
|
作者：
Komuro, Issei [1 ]
Bodegard, Johan [2 ]
Thuresson, Marcus [3 ]
Yajima, Toshitaka [4 ]
Eriksson, Jan W. [5 ]
Norhammar, Anna [6 ]
Birkeland, Kare I. [7 ]
Kadowaki, Takashi [8 ]
机构：
[1] Univ Tokyo, Dept Cardiovasc Med, Tokyo, Japan
[2] AstraZeneca, Med, Oslo, Norway
[3] Statisticon, Uppsala, Sweden
[4] AstraZeneca, Chiyoda Ku, Tokyo, Japan
[5] Uppsala Univ Hosp, Dept Med Sci, Uppsala, Sweden
[6] Karolinska Inst, Stockholm, Sweden
[7] Univ Oslo, Dept Transplantat Med, Oslo, Norway
[8] Univ Tokyo, Dept Prevent Diabet & Lifestyle Related Dis, Tokyo, Japan
来源：
CIRCULATION | 2019年 / 140卷 / 25期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
20852
引用
收藏
页码：E980 / E980
页数：1
相关论文
共 50 条
  • [1] Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
    Gonzalez-Albarran, Olga
    Morales, Cristobal
    Perez-Maraver, Manuel
    Juan Aparicio-Sanchez, Jose
    Simo, Rafael
    DIABETES THERAPY, 2022, 13 (SUPPL 1) : 35 - 49
  • [2] Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
    Olga González-Albarrán
    Cristóbal Morales
    Manuel Pérez-Maraver
    José Juan Aparicio-Sánchez
    Rafael Simó
    Diabetes Therapy, 2022, 13 : 35 - 49
  • [3] SGLT2i Use and the Risk of Nephrolithiasis in Patients with T2D
    Paik, Julie M.
    Tesfaye, Helen
    Curhan, Gary
    Mastrorilli, Julianna M.
    Wexler, Deborah J.
    Kim, Seoyoung C.
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [4] Level of Glycemic Control in Type 2 Diabetes (T2D) Patients with Established Cardiovascular Disease (eCVD) or Chronic Kidney Disease (CKD) Prescribed an SGLT2i
    Iglay, Kristy
    Bansal, Neha
    Gulati, Tania
    Hannachi, Hakima
    Fernandes, Gail
    Rajpathak, Swapnil
    DIABETES, 2019, 68
  • [5] Eligibility and Utilization of SGLT2i and GLP1-RA in T2D by Cardiovascular and Renal Indications
    Blood, Alexander
    Chang, Lee-Shing
    Colling, Caitlin A.
    Gabovitch, Daniel
    Hamersky, Carol M.
    Durden, Emily
    Holt, Cassie
    Noone, Joshua
    Cannon, Christopher P.
    Wexler, Deborah J.
    Scirica, Benjamin M.
    Waterman, Fanta
    Stern, Gretchen
    Zelle, David
    DIABETES, 2022, 71
  • [6] Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Chan, Juliana C.
    Kooy, Adriaan
    Mccafferty, Kieran
    Schernthaner, Guntram
    Wanner, Christoph
    Joseph, Amer
    Scheerer, Markus F.
    Scott, Charlie
    Bakris, George
    DIABETES, 2021, 70
  • [7] Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4
    Pratley, Richard E.
    Bauer, Robert
    Inzucchi, Silvio E.
    Khunti, Kamlesh
    Kreiner, Eskil B.
    Laursen, Peter N.
    Meier, Juris J.
    DIABETES, 2020, 69
  • [8] SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
    Javier Escalada
    Diabetes Therapy, 2022, 13 : 1 - 3
  • [9] SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
    Escalada, Javier
    DIABETES THERAPY, 2022, 13 (SUPPL 1) : 1 - 3
  • [10] Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study
    Lars Bernfort
    Magnus Husberg
    Ann-Britt Wiréhn
    Ulf Rosenqvist
    Staffan Gustavsson
    Kristina Karlsdotter
    Lars-Åke Levin
    Diabetes Therapy, 2020, 11 : 1537 - 1549
12345